Prelectal

Quick links to important sections

Prelectal

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prelectal

Prelectal: What is This Medicine?

Property Description
Active Ingredients Perindopril and Indapamide
Form Tablet (Fixed-dose combination)
Pharmacological Class Antihypertensive agent (ACE inhibitor + Diuretic)
Common Use Management of High Blood Pressure
Origin Synthetic

Prelectal is a prescription-only single-pill combination (SPC) medication used for the consistent management of essential hypertension (high blood pressure). It is formulated as a synthetic tablet and falls within the high-level group of Antihypertensive agents. The drug is designed for oral administration and contains two distinct active ingredients: Perindopril and Indapamide.


Pharmacological Identity and Composition

The Perindopril component is categorized as an Angiotensin-Converting Enzyme (ACE) inhibitor, while Indapamide is a thiazide-like diuretic. This combination operates through a dual-action mechanism. The pairing of these two agents is an established approach for long-term blood pressure control.

This formulation is available commercially under several trade names internationally, including Noliprel, indicating that the Perindopril/Indapamide pairing is a widely adopted standard for combination antihypertensive therapy. The combination offers a distinct advantage over monotherapy for adult patients who require simultaneous vascular relaxation and fluid volume reduction to control their condition.


General Purpose of the Single-Pill

The primary general purpose of Prelectal is to achieve reliable blood pressure control in adult patients. By delivering both agents in a fixed-dose combination, the medication ensures both the vessel-relaxing vasodilation and the volume-reducing effects are applied simultaneously. Combining these types of agents provides an enhanced benefit for cardiovascular risk reduction in adults with hypertension. This synergistic efficacy is the drug's most distinguishing feature, as it leverages complementary mechanisms of action to provide comprehensive management of high blood pressure with a single, simplified pill.

Regulatory References

  1. Antihypertensive Medications - StatPearls - NCBI Bookshelf

What side effects are possible with Prelectal?

Possible Side Effects and Safety Information: Prelectal

The safety profile of this medicine, as documented in official government regulatory sources, is organized into categories to communicate the full range of potential risks.

Adverse Reaction Classification

Adverse reactions are classified according to their observed frequency during clinical trials and post-marketing surveillance, using the International Council for Harmonisation (ICH) frequency definitions:

  • Very Common: Occurring in ge 1 in 10 patients.
  • Common: Occurring in ge 1 in 100 to < 1 in 10 patients.
  • Uncommon, Rare, and Very Rare: These categories account for reactions with lower reporting rates.
  • Not Known: Used when the rate cannot be accurately estimated from available data.

All documented adverse reactions are grouped by System-Organ Class (SOC), such as Nervous System Disorders, Gastrointestinal Disorders, or Cardiac Disorders, which provides a comprehensive view of the body systems potentially affected by the medicine.

Serious Adverse Reactions

Official regulatory documents prominently highlight Serious Adverse Reactions, often termed Clinically Significant Adverse Reactions. These are outcomes that warrant specific warnings due to their potential severity, such as anaphylaxis or severe organ toxicity, and are critical components of the mandated labeling.

Regulatory Restrictions and Population-Specific Safety

  • Contraindications are explicit regulatory statements defining specific patient conditions or concurrent diseases where the medicine must not be used, as the risk is considered unacceptable.
  • Population-Specific Considerations detail unique risks or required precautions for use in distinct groups, including geriatric patients, pediatric patients, and pregnant or lactating women.
  • Safety-Related Limitations include precautions against engaging in hazardous activities, such as driving or operating machinery, if specific adverse reactions (e.g., dizziness or disturbed consciousness) are known to be associated with the medicine.
  • Dose- or Exposure-Related Patterns are included if regulatory data explicitly demonstrate that risks are increased with high doses or prolonged exposure.

This mandatory structure ensures that all essential safety risks, from the most common to the most severe and usage-specific, are formally defined and communicated by the authorizing government health agency.

Overdose and Emergency Response

Overdose Manifestations and Required Emergency Action

The official regulatory documentation defines Prelectal overdose primarily by its profound circulatory and renal effects. The most commonly documented manifestation is severe hypotension (excessively low blood pressure), which may be accompanied by dizziness, confusion, and a significant reduction in urine output (oliguria or anuria). Physiological findings may include critical electrolyte imbalance, notably hyponatremia and hypokalemia.

Life-threatening outcomes, as described in regulatory labels, stem from severe circulatory compromise and include Acute Renal Failure, Myocardial Infarction, and Cerebrovascular Accident resulting from the prolonged, severe drop in blood pressure. The risk of laryngeal angioedema, a rapid and potentially fatal swelling of the airway, is also explicitly documented.

In all instances of suspected overdose, seek immediate medical attention and contact a poison control center or emergency medical services. The regulatory text mandates the patient be placed in a supine position and, if severe hypotension persists, managed with an intravenous infusion of physiological saline to restore fluid volume. Since no specific antidote is known, treatment is strictly limited to close medical supervision and symptomatic and supportive treatment. Special attention is noted for elderly patients, who may show greater sensitivity to the effects of overdose.

Therapeutic Uses of Prelectal

Quick Facts: Prelectal

  • Addresses: High blood pressure (hypertension).
  • Supports: The management of essential hypertension.
  • Aids: Certain cardiovascular risk reduction goals.

Prelectal is a medication approved for the management of essential hypertension, a condition involving elevated blood pressure. Utilizing this treatment may assist in achieving and maintaining blood pressure within a desired range, which is an important component of overall cardiovascular health. Clinical use suggests that Prelectal contributes to the therapeutic goals of individuals with this condition. The medication is also utilized to support the reduction of specific vascular risks in patients with established cardiovascular disease or certain risk factors, such as diabetes. A healthcare provider should always be consulted for personalized medical guidance and to determine if Prelectal is an appropriate option for an individual's specific needs. This medication is used within an overall plan of care to address high blood pressure.

Eligibility and Restrictions for Use

Regulatory documents define a patient's eligibility for Prelectal (a dual-agent combination product) based on specific clinical and physiological exclusions.

Populations Who Must Not Use Prelectal (Contraindicated)

  • Hypersensitivity: Individuals with a history of allergy to the active substances, any other ACE inhibitor, or any sulfonamide-derived medicine.
  • Angioedema: Patients with any history of angioedema (swelling of the face, throat, or limbs), whether hereditary, idiopathic, or related to previous ACE inhibitor use.
  • Organ Impairment: Patients with severe renal impairment (creatinine clearance <30 mL/min), severe hepatic impairment, or hepatic encephalopathy.
  • Electrolyte Status: Patients with a pre-existing condition of hypokalaemia (abnormally low potassium levels).
  • Pregnancy/Lactation: Use is prohibited during the second and third trimesters of pregnancy and during breastfeeding.
  • Drug-Drug Restrictions: Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes or renal impairment. Co-administration with Sacubitril/Valsartan is also prohibited.

Restricted or Not Recommended Use

  • Age: The medicine is not recommended for children and adolescents, as safety and efficacy have not been formally established in this population.
  • Dialysis/Heart Failure: Use is typically not recommended for dialysis patients or those with untreated decompensated heart failure due to a lack of sufficient clinical experience.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Prelectal (Perindopril/Indapamide) is based on official regulatory documentation and is categorized by the specific restrictions required for its components.


Contraindicated Combinations and Restrictions

Category Restriction Summary (Official Regulatory Information)
ARNI Agents Co-administration with Sacubitril/Valsartan is strictly contraindicated due to the significantly increased risk of angioedema. A mandatory 36-hour wash-out period must be observed between discontinuing one medication and starting the other.
Aliskiren Contraindicated in patients with diabetes mellitus or documented renal impairment (GFR < 60 mL/ min/1.73 m^2), reflecting a necessary restriction on Dual RAAS Blockade in vulnerable populations.
Extracorporeal Treatments Use is prohibited during certain procedures, such as dialysis with high-flux membranes, due to the documented risk of severe anaphylactoid reactions associated with the ACE inhibitor component.

Documented Pharmacodynamic and Exposure Interactions

Interactions that require careful attention involve substances that disrupt electrolyte balance or potentiate adverse effects. The co-administration of Potassium-sparing diuretics or Potassium supplements/salt substitutes is generally not recommended due to the documented risk of hyperkalemia. The concomitant use of the medication with Lithium may lead to an increase in serum lithium levels and potential toxicity. Additionally, agents like mTOR inhibitors and NEP inhibitors may increase the risk of angioedema, requiring caution in their combined use. Alcohol may cause an additive hypotensive effect, which is officially documented.

Mechanism of Action

How Prelectal Works: The Mechanism of Action


Hormonal Modulation of Vascular Tone

The mechanism initiated by Perindopril operates by competitively inhibiting the Angiotensin-Converting Enzyme (ACE), thereby interrupting the body’s Renin-Angiotensin-Aldosterone System (RAAS). This disruption reduces the production of the vasoconstrictor, Angiotensin II, and concurrently elevates local levels of the vasodilator, Bradykinin. This action leads to the relaxation and widening of the arteries, and results in a reduction of peripheral vascular resistance.


Renal Volume and Electrolyte Adjustment

The mechanism contributed by Indapamide centers on the inhibition of the Sodium-Chloride Symporter (SLC12A3) in the kidney. By blocking this transporter, the drug prevents the reabsorption of sodium and water, increasing their excretion and resulting in increased water excretion (diuresis). Indapamide also exerts a direct vasodilatory effect through the modulation of ion channels in the arterial walls, which contributes to the reduction in vascular resistance.


Synergistic Peripheral Resistance Control

The combination's action is defined by its synergy, where Perindopril blocks the RAAS activation that Indapamide's volume reduction might trigger, allowing the full physiological expression of the volume reduction mechanism. This coordinated action reduces both the total fluid load (cardiac preload) and the resistance faced by the heart (afterload), which results in a coordinated influence on systemic pressure modulation.

Dosage and Administration Information

How to Use Prelectal

Prelectal, the fixed-dose combination of perindopril and indapamide, is intended for oral administration. The medication is designed for the long-term management of essential hypertension and is administered as a tablet taken once daily.


Standardized Administration Protocol

The single daily dose is typically taken preferably in the morning before a meal. This timing ensures consistent absorption. The tablet is intended to be swallowed whole; although some strengths may be scored to facilitate swallowing, they are not to be divided into equal doses for administration.


Dosing and Adjustment Rules

Treatment typically begins with the lowest available strength, such as the 2 mg/0.625 mg tablet. Dosing adjustment is a gradual process; if blood pressure control remains inadequate, the dose may be increased after approximately one month of use, up to a maximum dose of one 8 mg/2.5 mg tablet daily. This structured titration schedule establishes the approach to a maintenance regimen.


Population-Specific Guidelines

Guidelines exist for specific populations. For older adults, treatment is initiated using the lowest available strength. Furthermore, specific dose restrictions apply to patients with moderate renal impairment, where the maximum dose is limited to the 2 mg/0.625 mg strength daily. If a daily dose is missed, a double dose should not be taken to compensate; the next scheduled dose should be taken at the usual time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prelectal

Evidence for Use in Essential Hypertension (High Blood Pressure)

The research for this fixed-dose combination, containing Perindopril and Indapamide, includes several large-scale Randomized Controlled Trials (RCTs) and comparative studies. These studies were designed to examine key physiological outcomes related to high blood pressure, which is a condition marked by functional limitations and outcomes monitoring physiological strain or stress. The primary goal of this research examined SBP and DBP in adults with essential hypertension. Researchers also examined outcomes related to systemic or functional imbalance, such as the regression of Left Ventricular Hypertrophy (LVH), a change in heart structure sometimes associated with long-term high blood pressure.

Studies reported patterns observed in the observed populations, where data show patterns related to SBP and DBP measurements when compared to baseline. Some comparative studies described patterns where the combination was observed in some studies to be associated with a greater proportion of patients reaching target blood pressure levels than certain single-drug treatments. Research has also examined whether outcomes related to LVH markers changed over intermediate-term study periods, such as one year.


Evidence for Use in Cardiovascular Risk Reduction

Research has also explored whether the combination is associated with major vascular events in conditions associated with acute or disruptive episodes. The evidence is founded on large, long-term Randomized Controlled Trials (RCTs) which were often placebo-controlled. These studies were evaluated in order to assess the occurrence of hard clinical endpoints, which are outcomes reflecting daily functioning or activity level, such as a composite of major events like non-fatal stroke, non-fatal myocardial infarction (heart attack), and cardiovascular death.

The long-term trials reported patterns observed in the studies, where research highlights changes measured during the study period for major cardiovascular events in the group receiving the study treatment compared to the control group over follow-up periods averaging around four years. Pooled analyses of this data suggest findings that describe group patterns related to the rate of events for endpoints like stroke in the treatment group within the high-risk populations studied. Furthermore, in research focusing on the diabetic population, data describe patterns related to microvascular outcomes and all-cause mortality when compared to the control group.


Strength of Evidence and Research Gaps

The research base for this combination consists primarily of multiple large-scale, long-term Randomized Controlled Trials (RCTs) focusing on hard clinical endpoints. These studies contribute to understanding symptom patterns in a controlled environment. However, several research limitation frames are acknowledged in the scientific literature. Comparative evidence is lacking when looking at direct comparisons against all other fixed-dose combinations currently available. Furthermore, the evidence highlights what is known—and what is still uncertain—about long-term outcomes and effects in specific demographic subgroups.

Frequently Asked Questions (FAQ)

Common questions about Prelectal (FAQ)


Q: How quickly should I expect Prelectal to start working?

The official product information indicates that the active substance, perindopril, is absorbed quickly, with its active component reaching peak levels in the blood within 3 to 4 hours. However, the full blood pressure-lowering effect may develop gradually, and a healthcare professional monitors the effect over time.


Q: Does Prelectal cause weight gain or weight loss?

Official regulatory documents describe both weight gain and weight decrease as possible adverse reactions associated with the use of this medication. This is listed within the full safety information provided to doctors, but these effects are typically not among the most frequently reported side effects.


Q: What are some common side effects people report when taking Prelectal?

According to official sources, side effects classified as common (affecting up to 1 in 10 people) may include a dry cough, headache, and dizziness. Other commonly reported issues are tingling sensations (pins and needles) and minor stomach disturbances like nausea or indigestion.


Q: Can I take Prelectal if I already take an over-the-counter painkiller?

Official documents advise that caution is required when using non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, alongside this medicine. The combination may potentially increase the risk of kidney problems. Additionally, taking these products together may sometimes reduce the blood pressure-lowering effect of Prelectal.


Q: Are there any specific foods or drinks that should be avoided with Prelectal?

The official product information states the tablet is recommended to be taken before a meal because food can decrease its absorption into the body. Furthermore, the use of potassium supplements or certain salt substitutes containing potassium is generally not recommended. This restriction is due to the potential risk of developing high potassium levels in the blood (hyperkalemia).


Q: Does Prelectal interact with birth control pills?

Official sources indicate that Prelectal is not known to affect the effectiveness of hormonal contraceptives, such as birth control pills. However, some types of hormonal contraceptives may not be recommended for individuals managing high blood pressure.


Q: Can Prelectal cause changes in mood or sleep patterns?

Official regulatory documents describe adverse reactions that affect the central nervous system and psychiatric health. These include potential changes to sleep patterns, such as insomnia (difficulty sleeping). Mood alterations, anxiety, and depression are also noted as possible side effects.


Q: Is Prelectal a type of controlled substance?

Prelectal is classified by regulatory bodies as a prescription-only medication. Antihypertensive agents of this type are not generally included in the regulatory schedules for controlled substances.


Q: What is the difference between Prelectal and its generic version?

Regulatory agencies approve generic versions of medications after confirming they are bioequivalent to the brand-name product. This means the generic version is expected to have the same clinical effect and safety profile. The main difference between the brand and generic versions often relates to inactive ingredients (excipients), as regulatory standards focus on the active component's performance.


Q: How long does Prelectal stay in your system?

Official pharmacokinetic information shows that while the initial drug (perindopril) is quickly processed, its main active component is eliminated more slowly. This active component has an effective half-life of approximately 24 hours. This pharmacological property supports the use of Prelectal as a once-daily medication.


Q: Are the side effects of Prelectal permanent?

The majority of side effects described in the official safety documents are generally considered reversible. This means they are expected to resolve once the dose is lowered or the medication is stopped. For example, the dry cough associated with the perindopril component usually disappears after discontinuation.


Q: Does Prelectal have any known interactions with herbal supplements?

Specific interactions with all types of herbal supplements are not universally listed in official drug information. However, caution is advised, particularly with supplements that may alter potassium levels in the body, which is a known concern for this type of medication. Official guidance notes that it is important to disclose all products being used, including supplements, to a healthcare provider.


Q: Can Prelectal cause dependency or addiction?

Studies and regulatory classifications provide no evidence that Prelectal causes dependency or addiction. The components of the medicine are an ACE inhibitor and a diuretic, classes that are not associated with addictive properties. It is not classified as a controlled substance by government health agencies.


Q: Are there specific instructions for stopping the use of Prelectal?

Official patient information does not typically contain explicit, step-by-step instructions for discontinuing the medication. Instead, official regulatory guidance emphasizes that questions or concerns regarding the medicine, including its discontinuation, are best addressed by a healthcare professional, such as a doctor or pharmacist.


Q: Does Prelectal have a specific 'Boxed Warning'?

In the United States, official labeling requires the presence of a Boxed Warning regarding the risk of fetal toxicity, which indicates potential harm to an unborn baby. This warning applies if the medication is used during the second and third trimesters of pregnancy. Other global regulatory documents also highlight this severe risk prominently within the contraindications section.


Q: Can people with diabetes use Prelectal?

Official safety information indicates that patients with diabetes may use Prelectal. However, monitoring of blood sugar is relevant because the indapamide component may increase blood glucose levels. The medication is specifically contraindicated (must not be used) in patients with diabetes who are also taking a product containing Aliskiren.


Q: Are there any known genetic factors that affect how Prelectal works?

Official prescribing information does not list any specific genetic factors or testing required before use. However, research into the drug's components has included studies on populations with genetic hypertension. This work suggests that the way an individual responds to the medication may involve underlying genetic components.

How should Prelectal be stored and disposed of?

The storage and disposal of Prelectal (Perindopril and Indapamide tablets) must follow official labeled requirements to ensure product stability and safety. The medication must be kept in its original container and protected from environmental factors.

Official Storage Conditions

Item Requirement
Temperature Store below 25 C (77 F), typically at controlled room temperature.
Protection Keep the tablets protected from moisture; avoid high-humidity areas.
Safety Keep the medicine out of the sight and reach of children.

Disposal

Unused or expired Prelectal must not be thrown away in household trash or flushed down the toilet. Dispose of the product according to local requirements, typically by returning it to a pharmacy or designated collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prelectal found in:

A-Z Index: